Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
LYON, France--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that the abstract featuring previously announced preclinical data demonstrating positive results for PXL065, the deuterium-stabilized R-enantiomer of pioglitazone, in hypertrophic cardiomyopathy 1, has been accepted for presentation at the 2025 edition of the European Society of Cardiology (ESC) Congress (link), to be held jointly with World Congress of Cardiology, on September 1 st, 2025 at 11:15 am CEST, in Madrid, Spain.
Prof. Dr. Cordula Wolf, Director of the Center for Rare Congenital Heart Diseases at the TUM University Hospital German Heart Center, stated: 'The compelling results obtained in this study illustrate the potential of PXL065 in HCM, the most common genetic cardiac disorder. Current treatments have important limitations in efficacy, safety, or patient applicability. There is a clear unmet need for safe and effective disease-modifying therapies.'
Thomas Kuhn, CEO of Poxel, added: 'We are pleased to have the data with PXL065 in HCM be presented at one of the world's leading forums for cardiovascular science and medicine, which underscores both the quality and relevance of these findings. We look forward to further supporting PXL065 development for the treatment of HCM based on these promising results.'
Hypertrophic Cardiomyopathy (HCM) is a genetic disorder marked by myocardial hypertrophy, cardiac fibrosis, ventricular dysfunction, arrhythmias, and an increased risk of sudden cardiac death. It is caused by mutations in sarcomere protein genes, leading to altered cell metabolism, including oxidative stress and mitochondrial dysfunction. The estimated prevalence of HCM is 0.2%, or 1/500 adults, and its incidence is around 5 per 100,000 person-years.
In connection with the mechanism of action of PXL065 on the inhibition of the mitochondrial pyruvate carrier (MPC) and on the inhibition of Acyl CoA Synthetase 4 (ACSL4) thus acting on oxidative stress, inflammation and fibrosis, PXL065 was successfully assessed in an established mouse model of hypertrophic cardiomyopathy.
This preclinical study was funded by the German Center for Cardiovascular Research (DZHK) and conducted at the TUM University Hospital German Heart Center by leading HCM expert Prof. Dr. Cordula Wolf. Poxel and the TUM University Hospital German Heart Center collaborated on the pre-clinical study based on Poxel's existing data and patent portfolio on PXL065 and prior research conducted by Prof. Dr. Cordula Wolf and her group on the disease mechanisms and therapeutic use of TZD's in HCM.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
1
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
35 minutes ago
- Business Wire
Wolters Kluwer Updates Sentri7, Enhancing Pharmacy and Nursing Workflows
WALTHAM, Mass.--(BUSINESS WIRE)-- Wolters Kluwer Health today announced extensive updates to its Sentri7 ® Drug Diversion and Sentri7 ® Pharmacy solutions, reinforcing its commitment to innovation in medication safety, compliance, and patient care. These improvements further equip clinical teams with actionable, data-driven insights to streamline workflows for drug diversion and medication management, ultimately supporting better patient care. 'Our mission is to help healthcare organizations deliver safer, higher-quality care with solutions that optimize the workflows supporting patient care and compliance in today's demanding healthcare environment,' said Karen Kobelski, Vice President and General Manager of Clinical Surveillance Compliance & Data Solutions at Wolters Kluwer Health. " With our team's deep expertise in pharmacy, technology, and artificial intelligence, we're providing customers with critical insights and support to address challenges like medication management, drug diversion prevention, and the opioid crisis.' Sentri7 Drug Diversion delivers improved workflows The redesigned Sentri7 Drug Diversion solution introduces a more intuitive interface, enabling teams to detect and manage drug diversion threats with greater precision and efficiency. Healthcare organizations can now act faster and more effectively to mitigate risks, with features like: User-friendly dashboard: Consolidates essential risk factors and actionable insights into a single, user-friendly interface to streamline diversion detection follow-up. Refined HEAT™ scoring and trend analysis: Quickly identifies high-risk staff across multiple facilities with a Watch List that improves alert monitoring of priority areas of concern. Missing medication analysis: Saves time for busy nursing teams by reconciling medication transactions across care areas, enabling timely interventions. 'Sentri7 Drug Diversion has a very mature user interface. It is very straightforward. It is easy to use and train our diversion staff to use. The graphics are very clear to understand. The solution has a HEAT score that it gives when it suspects an employee of diversion. It promotes that information to us and tells us where there is suspicious activity rather than us having to look at the numbers and determine that on our own,' according to a pharmacy manager interviewed by KLAS Research, February 2025. Sentri7 Pharmacy updates support patient-centered care The updated Sentri7 Pharmacy solution delivers an efficient, patient-centric workflow to optimize medication therapies, safety and overall cost savings. Key updates include: User-friendly interface: Tailored to support rounding workflows for individual patients, in addition to managing targeted medication surveillance across the entire patient population. Enhanced documentation tools: Simplified and standardized data entry enhances reporting, enabling pharmacy teams to demonstrate impact with evidence-based metrics. Actionable Performance Insights: Provides clear key performance indicators on cost savings, departmental contributions, and patient outcomes. When asked about Wolters Kluwer's surveillance solution, one pharmacy analyst noted in a KLAS Research April 2025 interview, 'Wolters Kluwer is super engaging and allows for a lot of collaborative work with organizations. The vendor does a good job of meeting organizations where they are at and working toward solutions. Wolters Kluwer has just been great at engaging with end users on how to improve their Sentri7 Pharmacy Surveillance product. I would definitely recommend Sentri7 Pharmacy Surveillance.' Learn more about the enhanced Sentri7 solutions. About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram.
Yahoo
an hour ago
- Yahoo
Ontarians Want Provincial Government to Prioritize Spending on Public Hospitals Not Private Clinics: New Poll
Vast majority say there isn't enough staff in public hospitals, including 82 per cent of Ontario PC supporters TORONTO, June 09, 2025--(BUSINESS WIRE)--Nearly three in four Ontarians believe the government should prioritize spending on public hospitals rather than private clinics, in a poll conducted following the recent budget announcement of $280 million being shunted to private, for-profit clinics. Eighty-four per cent of Ontarians also said they believe public hospitals are understaffed. The Nanos poll was conducted between May 27 and June 1, surveying 1,017 Ontarians over the age of 18. The poll was commissioned by CUPE's Ontario Council of Hospital Unions (OCHU-CUPE), which released a supplementary report on the ongoing privatization of hospital services. "This poll shows there is overwhelming opposition to this government's plans to privatize hospital surgeries," said Michael Hurley, president of OCHU-CUPE, which represents 50,000 hospital and long-term care staff. "The public understands that spending on private, for-profit clinics and agencies is much more expensive, comes with poorer outcomes and duplicates infrastructure and administration. The vast majority wants our resources allocated to public health care." While the government expands funding to for-profit clinics, over four in five Ontarians (84%) believe there is not enough staff in public hospitals – including 82 per cent of Ontario PC supporters. In the recent budget health care funding increased two per cent, well below the annual health care inflation of 5.2 per cent, noted the union. After significant privatization of cataract surgeries, the government plans to expand private, for-profit delivery of other procedures including knee and hip replacements as well as diagnostics. In 2023, Premier Doug Ford suggested that up to 50 per cent of surgeries could be performed outside of hospitals. "This is startling given that for-profit surgeries in Ontario are twice as expensive as those performed in public hospitals," said Hurley. The OCHU-CUPE report highlights the findings of a 2024 Canadian Medical Association Journal study showing that privatization of cataract operations resulted in surgical rates increasing by 22 per cent for the wealthiest Ontarians while declining for everyone else. Access to surgeries for the poorest people in Ontario declined nine per cent. The study noted that hospitals provided equal access to care. At the media conference, the union showed a visual representation of this inequality through a map of Ontario's neighbourhoods, colour-coded by socioeconomic status. The yellow areas representing the wealthiest neighbourhoods showed the most affluent Ontarians are clustered in enclaves that are barely visible amidst a sea of blue (representing the bottom 80 per cent of residents). "People can't afford to pay thousands of dollars for health care," Hurley said. "The great majority of Ontarians reject this expensive privatization that bakes in inequalities and greatly reduces access." The Ontario Health Coalition has documented hundreds of cases of private, for-profit clinics billing patients for medically necessary services – which is illegal – and add-on services that patients felt compelled to purchase. Sixty-seven per cent of respondents to the Nanos poll said it was unacceptable for private clinics to charge people for medically necessary services. The union expressed concerns about the acceleration of privatization, citing the CMAJ study's findings showing that since expansion of public funding for cataract surgeries in Ontario, 22.5 per cent of these procedures were performed in private clinics. :gv/cope491 View source version on Contacts For more information please contact: Zee Noorsumar, CUPE Communications,znoorsumar@ 647-995-9859 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Ontarians Want Provincial Government to Prioritize Spending on Public Hospitals Not Private Clinics: New Poll
TORONTO--(BUSINESS WIRE)--Nearly three in four Ontarians believe the government should prioritize spending on public hospitals rather than private clinics, in a poll conducted following the recent budget announcement of $280 million being shunted to private, for-profit clinics. Eighty-four per cent of Ontarians also said they believe public hospitals are understaffed. The Nanos poll was conducted between May 27 and June 1, surveying 1,017 Ontarians over the age of 18. The poll was commissioned by CUPE's Ontario Council of Hospital Unions (OCHU-CUPE), which released a supplementary report on the ongoing privatization of hospital services. 'This poll shows there is overwhelming opposition to this government's plans to privatize hospital surgeries,' said Michael Hurley, president of OCHU-CUPE, which represents 50,000 hospital and long-term care staff. 'The public understands that spending on private, for-profit clinics and agencies is much more expensive, comes with poorer outcomes and duplicates infrastructure and administration. The vast majority wants our resources allocated to public health care.' While the government expands funding to for-profit clinics, over four in five Ontarians (84%) believe there is not enough staff in public hospitals – including 82 per cent of Ontario PC supporters. In the recent budget health care funding increased two per cent, well below the annual health care inflation of 5.2 per cent, noted the union. After significant privatization of cataract surgeries, the government plans to expand private, for-profit delivery of other procedures including knee and hip replacements as well as diagnostics. In 2023, Premier Doug Ford suggested that up to 50 per cent of surgeries could be performed outside of hospitals. 'This is startling given that for-profit surgeries in Ontario are twice as expensive as those performed in public hospitals,' said Hurley. The OCHU-CUPE report highlights the findings of a 2024 Canadian Medical Association Journal study showing that privatization of cataract operations resulted in surgical rates increasing by 22 per cent for the wealthiest Ontarians while declining for everyone else. Access to surgeries for the poorest people in Ontario declined nine per cent. The study noted that hospitals provided equal access to care. At the media conference, the union showed a visual representation of this inequality through a map of Ontario's neighbourhoods, colour-coded by socioeconomic status. The yellow areas representing the wealthiest neighbourhoods showed the most affluent Ontarians are clustered in enclaves that are barely visible amidst a sea of blue (representing the bottom 80 per cent of residents). 'People can't afford to pay thousands of dollars for health care,' Hurley said. 'The great majority of Ontarians reject this expensive privatization that bakes in inequalities and greatly reduces access.' The Ontario Health Coalition has documented hundreds of cases of private, for-profit clinics billing patients for medically necessary services – which is illegal – and add-on services that patients felt compelled to purchase. Sixty-seven per cent of respondents to the Nanos poll said it was unacceptable for private clinics to charge people for medically necessary services. The union expressed concerns about the acceleration of privatization, citing the CMAJ study's findings showing that since expansion of public funding for cataract surgeries in Ontario, 22.5 per cent of these procedures were performed in private clinics. :gv/cope491
